CLVR Stock Overview
Operates in the botanical cannabinoid and nutraceutical industries. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Clever Leaves Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$5.89 |
| 52 Week Low | US$0.000001 |
| Beta | 15.76 |
| 11 Month Change | -99.99% |
| 3 Month Change | -99.67% |
| 1 Year Change | -100.00% |
| 33 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Even With A 59% Surge, Cautious Investors Are Not Rewarding Clever Leaves Holdings Inc.'s (NASDAQ:CLVR) Performance Completely
Feb 26
There's No Escaping Clever Leaves Holdings Inc.'s (NASDAQ:CLVR) Muted Revenues
Jun 24Clever Leaves partners with House of Kush for international expansion
Sep 21Clever Leaves reports Q2 results
Aug 11Everyone Says Sell Your Cannabis Stocks! I See It Differently (Podcast Transcript)
Jul 26Clever Leaves exports cannabis to Israel partner Intercure
Jul 18Clever Leaves expands partnership with Cantourage
Jul 11Clever Leaves Remains A Hold As It Ramps Up German Medical Cannabis And Colombian Exports
Jun 10Clever Leaves: New Management Needs To Nail Cannabis Distribution, Not Just Production
Mar 28Clever Leaves Looks Overvalued Based On Fundamentals
Jan 12Clever Leaves CEO Kyle Detwiler - Multi-National Cannabis Wholesaler (Video)
Jul 08Clever Leaves Holdings: A Smart Way To Gain Exposure To Cannabis Market
Jun 27Clever Leaves dispatches commercial flower shipment to Australia through IDT Australia
Jun 21Clever Leaves trades higher on joining Russell Microcap Index
Jun 14Clever Leaves Holdings (CLVR) Presents At 2021 ICR Conference - Slideshow
Jan 13Clever Leaves inks multi-year partnership with Entourage Phytolab
Jan 12Clever Leaves: Not The Ideal Cannabis Position
Jan 06Shareholder Returns
| CLVR | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -1.4% | 0.3% |
| 1Y | -100.0% | 10.8% | 31.1% |
Return vs Industry: CLVR underperformed the US Pharmaceuticals industry which returned 10.8% over the past year.
Return vs Market: CLVR underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| CLVR volatility | |
|---|---|
| CLVR Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CLVR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine CLVR's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 296 | Andres Fajardo | cleverleaves.com |
Clever Leaves Holdings Inc. operates in the botanical cannabinoid and nutraceutical industries. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment cultivates, extracts, manufactures, commercializes, and distributes cannabinoid products comprising cannabis flowers, cannabidiol isolates, full spectrum and standardized extracts, and dry smokable flowers internationally.
Clever Leaves Holdings Inc. Fundamentals Summary
| CLVR fundamental statistics | |
|---|---|
| Market cap | US$175.00 |
| Earnings (TTM) | -US$19.80m |
| Revenue (TTM) | US$17.42m |
0.0x
P/S Ratio0.0x
P/E RatioIs CLVR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLVR income statement (TTM) | |
|---|---|
| Revenue | US$17.42m |
| Cost of Revenue | US$10.86m |
| Gross Profit | US$6.56m |
| Other Expenses | US$26.35m |
| Earnings | -US$19.80m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.28 |
| Gross Margin | 37.64% |
| Net Profit Margin | -113.66% |
| Debt/Equity Ratio | 5.0% |
How did CLVR perform over the long term?
See historical performance and comparison